AAAAAA

   
Results: 1-10 |
Results: 10
ANALYSIS OF INTERCURRENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTIONS IN PHASE-I AND PHASE-II TRIALS OF CANDIDATE AIDS VACCINES
Authors: GRAHAM BS MCELRATH MJ CONNOR RI SCHWARTZ DH GORSE GJ KEEFER MC MULLIGAN MJ MATTHEWS TJ WOLINSKY SM MONTEFIORI DC VERMUND SH LAMBERT JS COREY L BELSHE RB DOLIN R WRIGHT PF KORBER BT WOLFF MC FAST PE
Citation: Bs. Graham et al., ANALYSIS OF INTERCURRENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTIONS IN PHASE-I AND PHASE-II TRIALS OF CANDIDATE AIDS VACCINES, The Journal of infectious diseases, 177(2), 1998, pp. 310-319
SELECTIVE SEROTONIN REUPTAKE INHIBITORS POTENTIATE 8-OH-DPAT-INDUCED STIMULUS-CONTROL IN THE PIGEON
Authors: WOLFF MC LEANDER JD
Citation: Mc. Wolff et Jd. Leander, SELECTIVE SEROTONIN REUPTAKE INHIBITORS POTENTIATE 8-OH-DPAT-INDUCED STIMULUS-CONTROL IN THE PIGEON, European journal of pharmacology, 345(1), 1998, pp. 35-39
PHARMACOLOGICAL PROFILE OF LY301317, A POTENT AND SELECTIVE 5-HT1A AGONIST
Authors: WOLFF MC BENVENGA MJ CALLIGARO DO FULLER RW GIDDA JS HEMRICKLUECKE S LUCOT JB NELSON DL OVERSHINER CD LEANDER JD
Citation: Mc. Wolff et al., PHARMACOLOGICAL PROFILE OF LY301317, A POTENT AND SELECTIVE 5-HT1A AGONIST, Drug development research, 40(1), 1997, pp. 17-34
EFFECTS OF A 5-HT1A RECEPTOR AGONIST ON ACUTE AND DELAYED CYCLOPHOSPHAMIDE-INDUCED VOMITING
Authors: WOLFF MC LEANDER JD
Citation: Mc. Wolff et Jd. Leander, EFFECTS OF A 5-HT1A RECEPTOR AGONIST ON ACUTE AND DELAYED CYCLOPHOSPHAMIDE-INDUCED VOMITING, European journal of pharmacology, 340(2-3), 1997, pp. 217-220
DIFFERENTIATION OF 5-HT1A RECEPTOR LIGANDS BY DRUG DISCRIMINATION
Authors: WOLFF MC LEANDER JD
Citation: Mc. Wolff et Jd. Leander, DIFFERENTIATION OF 5-HT1A RECEPTOR LIGANDS BY DRUG DISCRIMINATION, European journal of pharmacology, 333(2-3), 1997, pp. 113-122
COMPARISON OF THE ANTIEMETIC EFFECTS OF A 5-HT1A AGONIST, LY228729, AND 5-HT3 ANTAGONISTS IN THE PIGEON
Authors: WOLFF MC LEANDER JD
Citation: Mc. Wolff et Jd. Leander, COMPARISON OF THE ANTIEMETIC EFFECTS OF A 5-HT1A AGONIST, LY228729, AND 5-HT3 ANTAGONISTS IN THE PIGEON, Pharmacology, biochemistry and behavior, 52(3), 1995, pp. 571-575
CASE-COHORT ANALYSIS OF CASE-COVERAGE STUDIES OF VACCINE EFFECTIVENESS
Authors: MOULTON LH WOLFF MC BRENNEMAN G SANTOSHAM M
Citation: Lh. Moulton et al., CASE-COHORT ANALYSIS OF CASE-COVERAGE STUDIES OF VACCINE EFFECTIVENESS, American journal of epidemiology, 142(9), 1995, pp. 1000-1006
DECISION-MAKING DURING A PHASE-III RANDOMIZED CONTROLLED TRIAL
Authors: BERRY DA WOLFF MC SACK D
Citation: Da. Berry et al., DECISION-MAKING DURING A PHASE-III RANDOMIZED CONTROLLED TRIAL, Controlled clinical trials, 15(5), 1994, pp. 360-378
ANTIEMETIC EFFECTS OF 5-HT1A AGONISTS IN THE PIGEON
Authors: WOLFF MC LEANDER JD
Citation: Mc. Wolff et Jd. Leander, ANTIEMETIC EFFECTS OF 5-HT1A AGONISTS IN THE PIGEON, Pharmacology, biochemistry and behavior, 49(2), 1994, pp. 385-391
SAFETY STUDY OF TIRILAZAD MESYLATE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (STIPAS)
Authors: HALEY EC PUTMAN S ANDERSON F MORRISON MR TUTTLE P PASSINI BT WILNER AN ALLEN FH ADAMS R CARL B BUEKE C NICHOLS F HESS D HYDER S BURCH G FOLEY C BIVINS DH WILSON JT SISK MA NOLAN DB ELIAS WS SHEPPARD GL CROWE NF MASSEY S HURST D ZONTINE D GUSTIN KH MCCLURE K GRANNER M WOLF S GWYNN M METTETAL RW TORNER JC KONGABLE G WILKINSON S HANSEN CA WOLFF MC GIBSON RS BERGIN JD TRUSKOWSKI L LIGHTFOOT G LIGHTFOOT A POLIN A SOLENSKI NJ STITELER J PETERS GR BRYAN WJ
Citation: Ec. Haley et al., SAFETY STUDY OF TIRILAZAD MESYLATE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (STIPAS), Stroke, 25(2), 1994, pp. 418-423
Risultati: 1-10 |